 GAITHERSBURG, Md., Sept. 13, 2021 GLOBE NEWSWIRE -- MaxCyte, Inc., NASDAQ: MXCT; LSE: MXCT, MXCN, a leading commercial cell engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced its financial results for its second quarter and six months ended June 30, 2021. 